Evidence map›Paper›PMID 30984205›Full record

ReviewFrontiers in immunology2019

Immunopathogenesis of Behcet's Disease.

Bainan Tong, Xiaoli Liu, Jun Xiao, Guanfang Su

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 7 pooled it
29.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 7 syntheses or guidelines pooled it, 277 citations in OpenAlex.

  1. Pooled it
  2. Behçet's Disease: A Comprehensive Review on the Role ofInternational journal of molecular sciences · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Behҫet's Disease, and the Role of TNF-α and TNF-α Blockers.International journal of molecular sciences · 2020
    Pooled it
  7. IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.International journal of molecular sciences · 2019
    Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Observational
  19. Systemic Immune-Inflammation Index as a Marker of Activity in Behcet's Uveitis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026
    Article
  20. Review

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bainan TongDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Xiaoli LiuDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Jun XiaoDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Guanfang SuDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Second Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Behcet's disease (BD) is a chronic systemic inflammatory vasculitis of unknown etiology characterized by recurrent episodes of oral aphthous ulcers, genital ulcers, skin lesions, ocular lesions, and other manifestations. Although the pathogenesis of BD is unclear, some studies have shown that immunological aberrations play an important role in the development and progression of BD. Infection-related trigger factors, including antigens and autoantigens, are believed to mediate the development of BD in patients with a genetic predisposition and subsequently activate the innate and adaptive immune systems, resulting in the production of numerous cytokines and chemokines to combat the infection-related factors. The study of the immunological mechanism of BD paves the way for the development of innovative therapies. Recently, novel biotherapy approaches, including interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) antagonists, and other agents that target interleukins and their receptors, have shown promising results in the treatment of patients with refractory BD and have improved the prognosis of BD. In this review, we provide the current concepts of BD immunopathogenesis.

Indexed as

Behcet SyndromeCytokinesGenetic Predisposition to DiseaseAdaptive ImmunityAutoantigensHumansImmunity, InnateAutoantigensCytokinesautoimmune diseasesBehcet's diseasebiotherapy/target therapiescytokinespathogenesis

Identifiers

PMID30984205
PMCPMC6449449
OpenAlexW2926902750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.